Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | IAPP | P10997 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443420 | 0.82 | — | — | |
| SCHEMBL216266 | 0.82 | FFAR1 (0.39) | — | |
| SCHEMBL14306754 | 0.81 | IAPP (0.38) | IAPP | |
| Hydrochloric Acid SCHEMBL6625511 | 0.81 | FFAR1 (0.38) | SMN1; SMN2KDM4E | |
| SCHEMBL2154182 | 0.81 | CAPN1 (0.46) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| Hydrochloric Acid SCHEMBL1311654 | 0.81 | FFAR1 (0.38) | SMN1; SMN2KDM4E | |
| SCHEMBL30503064 | 0.81 | — | — | |
| SCHEMBL4544138 | 0.81 | HRH3 (0.32) | ALDH1A1 | |
| SCHEMBL16127990 | 0.80 | MTNR1A (0.37) | LMNAKDM4ENPC1TP53CYP1A2 | |
| SCHEMBL1039137 | 0.80 | TSHR (0.40) | ALDH1A1SMN1; SMN2HTTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK A/S (DK) | 2023-10-19 | — | — | US | disclosed |
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK A/S (DK) | 2023-10-19 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20210214726-A1 | Peptide Docking Vehicle for Targeted Nucleic Acid Delivery | SIRNAOMICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20170323732-A1 | USE OF HALOGEN DERIVATIVES OF HISTIDINE AS ELECTROLYTIC SALT IN A PHOTOVOLTAIC DYE CELL | UNIVERSITE DE PICARDIE JULES VERNE (FR) | 2017-11-09 | — | — | US | disclosed |
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-9072794-B2 | Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity | HANMI SCIENCE CO., LTD (KR) | 2015-07-07 | — | — | US | disclosed |
| US-9045463-B2 | Phenyl ethynyl derivatives as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2015-06-02 | — | — | US | disclosed |
| US-7235627-B2 | Derivatives of GLP-1 analogs | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-7235627-B2 | Derivatives of GLP-1 analogs | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885PDE4A 337/4885PDE4B 364/4885 |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | ALDH1A1 4813/4885PDE4A 466/4885PDE4B 645/4885 |
| US-20170323732-A1 | USE OF HALOGEN DERIVATIVES OF HISTIDINE AS ELECTROLYTIC SALT IN A PHOTOVOLTAIC DYE CELL | HDHD5, HCLS1, HCN1 | ALDH1A1 905/4885PDE4A 4250/4885PDE4B 4292/4885 |
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GIPR, GCGR | ALDH1A1 3429/4885PDE4A 507/4885PDE4B 861/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | ALDH1A1 3692/4885PDE4A 494/4885PDE4B 681/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885PDE4A 337/4885PDE4B 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.